<DOC>
	<DOCNO>NCT00983294</DOCNO>
	<brief_summary>Azithromycin possible weak moderate inhibitor CYP3A4 , one enzymes responsible metabolism colchicine . This study evaluate effect multiple dos azithromycin pharmacokinetic profile single 0.6 mg dose colchicine . A secondary objective evaluate safety tolerability regimen healthy volunteer . All study subject monitor adverse event throughout study period .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Colchicine Azithromycin</brief_title>
	<detailed_description>Azithromycin possible weak moderate inhibitor CYP3A4 , one enzymes responsible metabolism colchicine . This study evaluate effect multiple dos azithromycin pharmacokinetic profile single 0.6 mg dose colchicine . On day 1 , fast least 10 hour , twenty-four healthy non-smoking , non-obese , non-pregnant adult volunteer age 18 45 give single oral dose colchicine 0.6 mg. Fasting continue 4 hour dose . Blood sample draw participant dose twenty-four hour post-dose confined basis time sufficient adequately define pharmacokinetics colchicine . Blood sample continue non-confined basis Days 2-5 . After 2 week washout period , begin Day 15 continue day 18 , subject return clinic daily non-confined dosing azithromycin give orally 2 x 250 mg tablet Day 15 follow 1 x 250 mg tablet Days 16-18 . Administered azithromycin dos day necessarily fast state . On Day 15 take first dose azithromycin , subject remain clinic observation 1 hour post-dose administration . On Day 19 , fast least 10 hour , study subject receive co-administered single dose colchicine ( 0.6 mg ) azithromycin ( 1 x 250 mg tablet ) . All subject confine clinic 24-hour period follow dose . Blood drawn time sufficient define pharmacokinetics colchicine presence azithromycin steady state . Blood sample continue non-confined basis Days 20-23 . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout participation study adverse reaction study drug and/or procedure . Seated blood pressure pulse measure prior dose approximately 1 , 2 , 3 hour follow drug administration Days 1 19 . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Healthy adult 1845 year age , nonsmoking nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) body mass index ( BMI ) great equal 18 less equal 32 , inclusive Recent participation ( within 28 day ) research study Recent significant blood donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , gall bladder biliary tract , renal , haematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>blood level time ;</keyword>
	<keyword>colchicine ;</keyword>
	<keyword>azithromycin ;</keyword>
	<keyword>healthy</keyword>
</DOC>